- Home
- BVN vs IOVA Comparison
BVN vs IOVA Comparison
Compare BVN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- IOVA
- Stock Information
- Founded
- BVN 1953
- IOVA 2007
- Country
- BVN Peru
- IOVA United States
- Employees
- BVN N/A
- IOVA N/A
- Industry
- BVN Metal Mining
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BVN Basic Materials
- IOVA Health Care
- Exchange
- BVN Nasdaq
- IOVA Nasdaq
- Market Cap
- BVN 3.1B
- IOVA 2.6B
- IPO Year
- BVN 1996
- IOVA N/A
- Fundamental
- Price
- BVN $12.97
- IOVA $5.88
- Analyst Decision
- BVN Buy
- IOVA Strong Buy
- Analyst Count
- BVN 2
- IOVA 9
- Target Price
- BVN $16.50
- IOVA $23.33
- AVG Volume (30 Days)
- BVN 888.5K
- IOVA 9.1M
- Earning Date
- BVN 02-27-2025
- IOVA 02-26-2025
- Dividend Yield
- BVN 0.56%
- IOVA N/A
- EPS Growth
- BVN 329.23
- IOVA N/A
- EPS
- BVN 1.41
- IOVA N/A
- Revenue
- BVN $1,108,813,000.00
- IOVA $90,858,000.00
- Revenue This Year
- BVN N/A
- IOVA $13,758.71
- Revenue Next Year
- BVN N/A
- IOVA $171.20
- P/E Ratio
- BVN $8.89
- IOVA N/A
- Revenue Growth
- BVN 35.82
- IOVA 12751.20
- 52 Week Low
- BVN $11.50
- IOVA $5.57
- 52 Week High
- BVN $18.84
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- BVN 57.95
- IOVA 28.60
- Support Level
- BVN $12.77
- IOVA $5.62
- Resistance Level
- BVN $13.05
- IOVA $6.44
- Average True Range (ATR)
- BVN 0.46
- IOVA 0.45
- MACD
- BVN 0.09
- IOVA -0.08
- Stochastic Oscillator
- BVN 86.78
- IOVA 12.02
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.